PDE5 Inhibitors & Endothelial Function

Navigation

Upward Index: 02 - Compounds & Molecules MOC | Literature Dossier: PDE5 Inhibitors & Endothelial Function - References

---

1. Pharmacodynamics & Mechanism of Action

Originally developed for angina pectoris and pulmonary arterial hypertension, Phosphodiesterase Type 5 Inhibitors (PDE5i)—most notably long-acting Tadalafil—have emerged as foundational vascular longevity, cardioprotective, and neurovascular therapeutics (“A man is as old as his endothelium” — Sir William Osler).

• The eNOS $\to$ NO $\to$ sGC $\to$ cGMP $\to$ PKG Cascade: Shear stress or acetylcholine stimulates endothelial Nitric Oxide Synthase (eNOS) to convert L-arginine into Nitric Oxide ($\text{NO}$). $\text{NO}$ diffuses into adjacent vascular smooth muscle cells and activates soluble Guanylyl Cyclase (sGC), converting $\text{GTP}$ into the second messenger cyclic GMP ($\text{cGMP}$). $\text{cGMP}$ activates Protein Kinase G (PKG), which lowers intracellular ${\text{Ca}}^{2+}$ to relax smooth muscle, inhibit vascular smooth muscle proliferation, and suppress platelet adhesion. PDE5 enzymatically degrades $\text{cGMP}$ into inactive $5^{\prime }\text{-GMP}$; inhibiting PDE5 preserves and amplifies endogenous $\text{NO}$-driven $\text{cGMP}$ signaling across systemic, coronary, renal, prostatic, and cerebral microvascular beds.
• Endothelial Progenitor Cell (EPC) Mobilization & Arterial Stiffness: Chronic low-dose Tadalafil ($2.5\text{–}5\text{ mg/day}$) mobilizes bone-marrow-derived ${\text{CD34}}^{+}{\text{KDR}}^{+}$ Endothelial Progenitor Cells (EPCs) to repair damaged vascular intima, increases Brachial Artery Flow-Mediated Dilation (FMD), and lowers circulating Endothelin-1 (ET-1), CRP, and ICAM-1/VCAM-1.
• Benign Prostatic Hyperplasia (BPH) & Lower Urinary Tract Symptoms (LUTS): PDE5 is densely expressed in the prostatic stroma, bladder detrusor, and urethral vasculature; daily $5\text{ mg}$ Tadalafil improves pelvic oxygenation, relaxes prostatic smooth muscle tone, and reduces nocturnal awakenings (nocturia—directly preserving deep sleep architecture).
• Cerebral Perfusion, Glymphatic Clearance & Aromatase Modulation: Tadalafil crosses the blood-brain barrier ($t_{1/2}\approx 17.5\text{ h}$), improving subcortical white-matter microvascular perfusion in cerebral small-vessel disease, inhibiting microglial neuroinflammation via PKG-CREB signaling, and modestly improving the Testosterone-to-Estradiol ($T:E_2$) ratio via mild down-modulation of adipocyte/endothelial aromatase expression.

---

2. Pharmacokinetics & PDE Isoenzyme Selectivity

Compound	Plasma $t_{1/2}$	Food Interaction	PDE6 (Retinal) Cross-Reactivity	PDE11 (Skeletal Muscle) Cross-Reactivity	Optimal Biohacking Application
Tadalafil (Cialis)	$17.5\text{ hours}$ ($36\text{ h}$ window)	None (unaffected by high-fat meals)	Very Low ($700\times$ more selective for PDE5 than PDE6; rare visual tint)	Moderate ($5\text{–}40\times$ selective; can cause transient lower-back/gluteal myalgia in weeks 1–2)	Daily endothelial, BPH, blood pressure & gym pump longevity protocol ($2.5\text{–}5\text{ mg/day}$)
Sildenafil (Viagra/Revatio)	$3\text{–}5\text{ hours}$	High (fat delays $T_{\max }$ by $60\text{ min}$ and drops $C_{\max }$ by $-29\%$)	Moderate ($\sim 10\times$ PDE5/PDE6 ratio; can cause transient cyanopsia/blue vision)	Very Low	Acute jet-lag circadian phase-advancing (SCN cGMP) or high-altitude pulmonary vasodilation
Vardenafil	$4\text{–}5\text{ hours}$	Moderate	Moderate	Very Low	Acute use; prolongs QT interval slightly

---

3. Dosing, Cycling & Synergies

• Standard Microvascular Longevity Protocol:
  • Tadalafil: $2.5\text{ mg}$ to $5.0\text{ mg}$ once daily in the morning. Within 5 days, daily dosing achieves a steady-state plasma concentration equivalent to $1.6\times$ the single-dose exposure, providing continuous 24-hour endothelial eNOS-cGMP tone without peaks and troughs.
• Cycling Cadence: Unlike receptor agonists, PDE5 inhibitors do not induce pharmacological tachyphylaxis or PDE5 upregulation at physiological $2.5\text{–}5\text{ mg/day}$ doses and can be administered continuously.
• Obligate Upstream Synergy ($\text{NO}$ Substrate Supply): Because PDE5 inhibitors only block the breakdown of $\text{cGMP}$, they require upstream Nitric Oxide ($\text{NO}$) synthesis to generate $\text{cGMP}$ in the first place. Pair daily low-dose Tadalafil with:
  • Amino Acids & Precursors (L-Citrulline $3\text{–}6\text{ g/day}$): Supplies the eNOS pathway.
  • Dietary Nitrates ($400\text{–}800\text{ mg }{\text{NO}}_3^{-}$ from beetroot/arugula): Supplies the enterosalivary ${\text{NO}}_3^{-}\to {\text{NO}}_2^{-}\to \text{NO}$ pathway (avoid antiseptic chlorhexidine mouthwash, which kills oral nitrate-reducing bacteria and raises blood pressure).
  • Pycnogenol ($100\text{ mg/day}$): Directly phosphorylates and activates eNOS.
• Contraindications & Biomarkers to Monitor:
  • Strict Contraindications: Organic Nitrates (nitroglycerin, isosorbide mononitrate/dinitrate, amyl nitrite) and sGC stimulators (riociguat)—co-administration causes life-threatening refractory hypotension. Caution with non-selective ${\alpha }_1$-blockers (doxazosin/terazosin), history of NAION (non-arteritic anterior ischemic optic neuropathy), or severe GERD (PDE5 inhibition mildly relaxes the lower esophageal sphincter).
  • Biomarkers: Central & Brachial Blood Pressure (typically lowers SBP by $-4\text{ to }-7\text{ mmHg}$ and DBP by $-3\text{ to }-5\text{ mmHg}$), Flow-Mediated Dilation (FMD) / EndoPAT Reactive Hyperemia Index, Urine Albumin-to-Creatinine Ratio (uACR — marker of glomerular endothelial glycocalyx integrity), IPSS (International Prostate Symptom Score), and hs-CRP.

---

4. Key Scientific Evidence Summary

• Endothelial Restoration in Cardiovascular Risk: Rosano et al. (2005) demonstrated in European Urology / European Heart Journal ($N=32$) that 4 weeks of chronic Tadalafil increased brachial artery Flow-Mediated Dilation (FMD) from $4.2\%$ to $9.3\%$ ($p<0.01$), reduced Endothelin-1 by $-34\%$, and sustained endothelial improvements for 2 weeks after drug cessation.
• Major Adverse Cardiovascular Events (MACE) & All-Cause Mortality: Kloner et al. (2023, $N=72,498$) and Andersson et al. (2017, Heart, $N=43,145$ post-MI patients) demonstrated that PDE5i use was associated with a $-25\text{ to }-33\%$ reduction in all-cause mortality and a $-40\%$ reduction in heart failure hospitalization, with a clear dose-response advantage for regular Tadalafil users.
• Alzheimer’s & Dementia Risk Reduction: Adesuyan et al. (2024) published in Neurology ($N=269,725$) that PDE5 inhibitor initiation was associated with an $-18\%$ lower hazard of Alzheimer’s disease ($\text{HR }0.82$), rising to $-44\%$ ($\text{HR }0.56$) in individuals with the highest cumulative prescription adherence.

See full study breakdowns in PDE5 Inhibitors & Endothelial Function - References.